Japanese Encephalitis Virus Vaccination Elicits Cross-Reactive HLA-Class I-Restricted CD8 T Cell Response Against Zika Virus Infection

Tarbe, Marion; Dong, Wei; Hu, Guang; Xu, Yongfen; Sun, Jing; Grayo, Solène; Chen, Xianyang; Qin, Cheng‐Feng; Zhao, Jincun; Liu, Li; Li, Xiuzhen; Leng, Qibin

doi:10.3389/fimmu.2020.577546

Cited by 8 publications

(6 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cellular immunity played an important role in the cross-protective effect of prior JEV immunity on the sequential ZIKV infection [44,45]. In the JEV-vaccinated ifnar −/− adult mouse model, depletion of CD8 + T cells increased mortality, weight loss, and severity of clinical symptoms during ZIKV infection, indicating that CD8 + T cells were indispensable for the protective effect in the sequential infection of JEV-ZIKV [6].…”

Section: The Impact Of Prior Jev Immunity On Zikv Infectionmentioning

confidence: 99%

Cross-Reactive Immunity among Five Medically Important Mosquito-Borne Flaviviruses Related to Human Diseases

Hou

Chen

Gao

et al. 2022

Viruses

View full text Add to dashboard Cite

Flaviviruses cause a spectrum of potentially severe diseases. Most flaviviruses are transmitted by mosquitoes or ticks and are widely distributed all over the world. Among them, several mosquito-borne flaviviruses are co-epidemic, and the similarity of their antigenicity creates abundant cross-reactive immune responses which complicate their prevention and control. At present, only effective vaccines against yellow fever and Japanese encephalitis have been used clinically, while the optimal vaccines against other flavivirus diseases are still under development. The antibody-dependent enhancement generated by cross-reactive immune responses against different serotypes of dengue virus makes the development of the dengue fever vaccine a bottleneck. It has been proposed that the cross-reactive immunity elicited by prior infection of mosquito-borne flavivirus could also affect the outcome of the subsequent infection of heterologous flavivirus. In this review, we focused on five medically important flaviviruses, and rearranged and recapitulated their cross-reactive immunity in detail from the perspectives of serological experiments in vitro, animal experiments in vivo, and human cohort studies. We look forward to providing references and new insights for the research of flavivirus vaccines and specific prevention.

show abstract

Section: The Impact Of Prior Jev Immunity On Zikv Infectionmentioning

confidence: 99%

Cross-Reactive Immunity among Five Medically Important Mosquito-Borne Flaviviruses Related to Human Diseases

Hou

Chen

Gao

et al. 2022

Viruses

View full text Add to dashboard Cite

show abstract

“…184 Furthermore, JEV SA14-14-2 vaccine was found to provide cross-protection against ZIKV infection in mice and potential with low risk of ADE in immunecompetent humans. 186 In addition, there are no specific therapeutic drugs for dengue, and the treatment is only supportive care for severe dengue patients. Therefore, various forms of publicity and education should be carried out widely to popularize the knowledge of health emergencies contributes greatly to the control of dengue.…”

Section: Personal Protectionmentioning

confidence: 99%

“…Nevertheless, studies with different results have also been reported, such as anti‐JEV antibodies predisposed to symptomatic DF, 185 and the pre‐existing of JEV neutralizing antibodies increases the risk of DF by 2.75‐fold 184 . Furthermore, JEV SA14‐14‐2 vaccine was found to provide cross‐protection against ZIKV infection in mice and potential with low risk of ADE in immune‐competent humans 186 . In addition, there are no specific therapeutic drugs for dengue, and the treatment is only supportive care for severe dengue patients.…”

Section: Prevention and Controlmentioning

confidence: 99%

Dengue fever and dengue virus in the People's Republic of China

2021

Reviews in Medical Virology

View full text Add to dashboard Cite

Infection with dengue virus (DENV) leads to symptoms variable from dengue fever to severe dengue, which has posed a huge socioeconomic and disease burden to the world population, particularly in tropical and subtropical regions. To date, four serotypes of DENV (DENV-1 to DENV-4) have been identified to sustain the transmission cycle in humans. In the past decades, dengue incidences have become more frequent, and four serotypes and various genotypes have been identified in PR China. Several large-scale dengue outbreaks and frequent local endemics occurred in the southern and coastal provinces, and the imported dengue cases accounted primarily for the initiation of the epidemics. No antiviral drug exists for dengue, and no vaccine has been approved to use in PR China, however strategies including public awareness, national reporting system of infectious diseases and public health emergencies, vector mosquito control, personal protection, and improved environmental sanitation have greatly reduced dengue prevalence. Some new technologies in vector mosquito control are emerging and being applied for dengue control.China's territory spans tropical, subtropical, and temperate climates, hence understanding the dengue status in China will be of beneficial for the global prevention and control of dengue. Here, we review the dengue status in PR China for the past decades and the strategies emerging for dengue control.

show abstract

“…Thus, this vaccine may induce immunodominant responses toward non-structural proteins at the expense of structural antigens that have homology with those presented by the ZPIV vaccine. Our study also suggests that the presence of non-structural antigens or active virus replication may be needed to induce CD8 T cell responses, as robust CD8 T cell activation has been demonstrated upon ZIKV infection in human and mice studies ( 53 , 54 ), and cross-reactive CD8 T cell responses between a live attenuated JEV vaccine and ZIKV infection were described ( 55 ), but this type of response was not elicited by the ZPIV vaccine. The live-attenuated YFV vaccine is known to induce robust CD8 T cell responses ( 56 ).…”

Section: Discussionmentioning

confidence: 57%

Pre-existing Immunity to Japanese Encephalitis Virus Alters CD4 T Cell Responses to Zika Virus Inactivated Vaccine

et al. 2021

View full text Add to dashboard Cite

The epidemic spread of Zika virus (ZIKV), associated with devastating neurologic syndromes, has driven the development of multiple ZIKV vaccines candidates. An effective vaccine should induce ZIKV-specific T cell responses, which are shown to improve the establishment of humoral immunity and contribute to viral clearance. Here we investigated how previous immunization against Japanese encephalitis virus (JEV) and yellow fever virus (YFV) influences T cell responses elicited by a Zika purified-inactivated virus (ZPIV) vaccine. We demonstrate that three doses of ZPIV vaccine elicited robust CD4 T cell responses to ZIKV structural proteins, while ZIKV-specific CD4 T cells in pre-immunized individuals with JEV vaccine, but not YFV vaccine, were more durable and directed predominantly toward conserved epitopes, which elicited Th1 and Th2 cytokine production. In addition, T cell receptor repertoire analysis revealed preferential expansion of cross-reactive clonotypes between JEV and ZIKV, suggesting that pre-existing immunity against JEV may prime the establishment of stronger CD4 T cell responses to ZPIV vaccination. These CD4 T cell responses correlated with titers of ZIKV-neutralizing antibodies in the JEV pre-vaccinated group, but not in flavivirus-naïve or YFV pre-vaccinated individuals, suggesting a stronger contribution of CD4 T cells in the generation of neutralizing antibodies in the context of JEV-ZIKV cross-reactivity.

show abstract

Japanese Encephalitis Virus Vaccination Elicits Cross-Reactive HLA-Class I-Restricted CD8 T Cell Response Against Zika Virus Infection

Cited by 8 publications

References 27 publications

Cross-Reactive Immunity among Five Medically Important Mosquito-Borne Flaviviruses Related to Human Diseases

Cross-Reactive Immunity among Five Medically Important Mosquito-Borne Flaviviruses Related to Human Diseases

Dengue fever and dengue virus in the People's Republic of China

Pre-existing Immunity to Japanese Encephalitis Virus Alters CD4 T Cell Responses to Zika Virus Inactivated Vaccine

Contact Info

Product

Resources

About